The agenda includes:
Preparing positions on the evaluation of medicines:
- Onureg (azacitidine) under the drug programme B.114. “Treatment of patients with acute myeloblastic leukaemia (ICD-10 C 92.0)”,
- Suliqua (insulinum glarginum + lixisenatidum) for the indication: treatment of adult patients with uncontrolled type 2 diabetes despite treatment with basal insulin (BI) in combination with at least one oral hypoglycaemic drug (OAD) with HbA1c >7%,
- Tremfya (guselkumab) under the drug programme: “Treatment of active psoriatic arthritis (ICD-10 L40.5, M07.1, M07.2, M07.3)”.